Post by
Noteable on Jul 25, 2023 12:43pm
BMS buys stock in TCR-based cell therapies & bispecifics co.
July 24, 2023 - “Immatics”, a Phase 1 biopharmaceutical company, in the discovery and development of T cell-redirecting cancer immunotherapies, announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in the company
Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of US$14.46
https://www.globenewswire.com/news-release/2023/07/24/2709406/0/en/Immatics-Announces-35-Million-Equity-Investment-from-Bristol-Myers-Squibb.html
https://immatics.com/our-pipeline/
Comment by
Noteable on Jul 25, 2023 1:14pm
Phase 1 company "Immatics" has 76 Million shares outstanding and a market cap of US$1 Billion.
Comment by
Noteable on Jul 25, 2023 2:59pm
Matt Coffey once proposed Big Pharma taking an equty position in ONCY. Has it happened? Not yet.
Comment by
Noteable on Jul 27, 2023 3:36pm
Like BMS Big Pharma's M&A targets are increasingly moving towards biological assets, specifically in cancer and immunology, which are granted 13 years of FDA market exclusivity as compared to 9 years exclusivity for small molecules.
Comment by
Noteable on Jul 27, 2023 7:35pm
876K shares of ONCY traded in one trade at approximately 10:45 am this morning.
Comment by
canadafan on Jul 28, 2023 9:47am
A 876kk trade obviously a prearranged institutional buy . no other explanation